血小板药物递送系统的研究进展

doi:10.3969/j.issn.1000-8535.2024.06.001

摘要/Abstract

摘要： 药物递送系统对于各类疾病意义非凡,但传统药物载体面临细胞毒性强、组织相容性低、半衰期短和靶向性弱等诸多挑战。血小板及其相关衍生物作为新型药物载体具有更为显著的优势。由于血小板自身的生理特点,以及在肿瘤、心血管疾病、血栓性疾病、感染等多种疾病中发挥的病理生理作用,血小板能够弥补传统药物载体的缺陷,具有极大的临床转化意义。该文总结了血小板相关药物递送系统目前的研究进展,以期为新型药物载体研究提供参考。

关键词: 血小板, 仿生纳米颗粒, 血小板衍生物, 药物递送系统

Abstract: Drug delivery systems are important for various diseases,but conventional therapeutic drug have many shortcomings,such as high cytotoxicity,low histocompatibility,short half-life and weak targeting．Platelets and their derivatives have more significant advantages as novel drug carriers．Platelets play an important role in the pathophysiology of a wide range of diseases including oncology,cardiovascular diseases,thrombosis and infection．In this paper,we summarized the current research progress of platelet-related drug delivery systems to provide a reference for the research of novel drug delivery systems．

Key words: platelet, bionic nano carriers, platelet extracellular vesicles, drug delivery system

贾翠萍, 张媛, 邓伟豪. 血小板药物递送系统的研究进展[J]. 广州医药, 2024, 55(6): 577-584.

JIA Cuiping, ZHANG Yuan, TANG Waiho. Advances in platelet as drug delivery systems[J]. Guangzhou Medical Journal, 2024, 55(6): 577-584.

参考文献

[1] TORCHILIN V P.Recent advances with liposomes as pharmaceutical carriers[J].Nat Rev Drug Discov,2005,4(2):145-160.
[2] KOZUBEK A,GUBERNATOR J,PRZEWORSKA E,et al.Liposomal drug delivery,a novel approach:PLARosomes[J].Acta Biochim Pol,2000,47(3):639-649.
[3] NOUNOU M M,EL-KHORDAGUI L K,KHALAFALLAH N A,et al.In vitro release of hydrophilic and hydrophobic drugs from liposomal dispersions and gels[J].Acta Pharm,2006,56(3):311-324.
[4] SUK J S,XU Q,KIM N,et al.PEGylation as a strategy for improving nanoparticle-based drug and gene delivery[J].Adv Drug Deliv Rev,2016,99(Pt A):28-51.
[5] JOKERST J V,LOBOVKINA T,ZARE R N,et al.Nanoparticle PEGylation for imaging and therapy[J].Nanomedicine(Lond),2011,6(4):715-728.
[6] SONG H,GUO T,ZHAO Z,et al.Biocompatible PEGylated gold nanorods function as cytokinesis inhibitors to suppress angiogenesis[J].Biomaterials,2018(178):23-35.
[7] HU C M J,FANG R H,WANG K C,et al.Nanoparticle biointerfacing by platelet membrane cloaking[J].Nature,2015,526(7571):118-121.
[8] GRATTON S E A,ROPP P A,POHLHAUS P D,et al.The effect of particle design on cellular internalization pathways[J].Proc Natl Acad Sci USA,2008,105(33):11613-11618.
[9] SEMPLE J W,ITALIANO J E,FREEDMAN J.Platelets and the immune continuum[J].Nat Rev Immunol,2011,11(4):264-274.
[10] KOUPENOVA M,CLANCY L,CORKREY H A,et al.Circulating platelets as mediators of immunity,inflammation,and thrombosis[J].Circ Res,2018,122(2):337-351.
[11] KOUPENOVA M,CORKREY H A,VITSEVA O,et al.SARS-CoV-2 initiates programmed cell Death in platelets[J].Circ Res,2021,129(6):631-646.
[12] MACHLUS K R,ITALIANO J E.The incredible journey:From megakaryocyte development to platelet formation[J].J Cell Biol,2013,201(6):785-796.
[13] van der MEIJDEN P E J,HEEMSKERK J W M.Platelet biology and functions:New concepts and clinical perspectives[J].Nat Rev Cardiol,2019,16(3):166-179.
[14] RENDU F,BROHARD-BOHN B.The platelet release reaction:Granules’ constituents,secretion and functions[J].Platelets,2001,12(5):261-273.
[15] ITALIANO J E,RICHARDSON J L,PATEL-HETT S,et al.Angiogenesis is regulated by a novel mechanism:Pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released[J].Blood,2008,111(3):1227-1233.
[16] BROWN G T,MCINTYRE T M.Lipopolysaccharide signaling without a nucleus:Kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles[J].J Immunol,2011,186(9):5489-5496.
[17] FRENCH S L,BUTOV K R,ALLAEYS I,et al.Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation[J].Blood Adv,2020,4(13):3011-3023.
[18] OLSSON M,BRUHNS P,FRAZIER W A,et al.Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia[J].Blood,2005,105(9):3577-3582.
[19] CRUZ M A,CHEN J,WHITELOCK J L,et al.The platelet glycoprotein Ib-von Willebrand factor interaction activates the collagen receptor alpha2beta1 to bind collagen:Activation-dependent conformational change of the alpha2-I domain[J].Blood,2005,105(5):1986-1991.
[20] ALVES C S,BURDICK M M,THOMAS S N,et al.The dual role of CD44 as a functional P-selectin ligand and fibrin receptor in colon carcinoma cell adhesion[J].Am J Physiol Cell Physiol,2008,294(4):C907-C916.
[21] KAPPELMAYER J,NAGY B.The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression[J].Biomed Res Int,2017(2017):6138145.
[22] ZUFFEREY A,FONTANA P,RENY J-L,et al.Platelet proteomics[J].Mass Spectrom Rev,2012,31(2):331-351.
[23] FRANCO A T,CORKEN A,WARE J.Platelets at the interface of thrombosis,inflammation,and cancer[J].Blood,2015,126(5):582-588.
[24] HOLINSTAT M.Normal platelet function[J].Cancer Metastasis Rev,2017,36(2):195-198.
[25] HARDING S A,SOMMERFIELD A J,SARMA J,et al.Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus[J].Atherosclerosis,2004,176(2):321-325.
[26] van GILS J M,ZWAGINGA J J,HORDIJK P L.Molecular and functional interactions among monocytes,platelets,and endothelial cells and their relevance for cardiovascular diseases[J].J Leukoc Biol,2009,85(2):195-204.
[27] GAERTNER F,MASSBERG S.Patrolling the vascular borders:Platelets in immunity to infection and cancer[J].Nat Rev Immunol,2019,19(12):747-760.
[28] GREMMEL T,FRELINGER A L,MICHELSON A D.Platelet physiology[J].Semin Thromb Hemost,2016,42(3):191-204.
[29] BOILARD E,DUCHEZ A-C,BRISSON A.The diversity of platelet microparticles[J].Curr Opin Hematol,2015,22(5):437-444.
[30] AATONEN M T,OHMAN T,NYMAN T A,et al.Isolation and characterization of platelet-derived extracellular vesicles[J].J Extracell Vesicles,2014:3.
[31] YARMUSH M L,GOLBERG A,SERŠA G,et al.Electroporation-based technologies for medicine:principles,applications,and challenges[J].Annu Rev Biomed Eng,2014(16):295-320.
[32] YAO C,WANG C.Platelet-derived extracellular vesicles for drug delivery[J].Biomater Sci,2023,11(17):5758-5768.
[33] SARKAR S,ALAM M A,SHAW J,et al.Drug delivery using platelet cancer cell interaction[J].Pharm Res,2013,30(11):2785-2794.
[34] XU P,ZUO H,CHEN B,et al.Doxorubicin-loaded platelets as a smart drug delivery system:An improved therapy for lymphoma[J].Sci Rep,2017(7):42632.
[35] LI Y T,NISHIKAWA T,KANEDA Y.Platelet-cytokine complex suppresses tumour growth by exploiting intratumoural thrombin-dependent platelet aggregation[J].Sci Rep,2016(6):25077.
[36] ABDELGAWWAD M S,CAO W,ZHENG L,et al.Transfusion of platelets loaded with recombinant ADAMTS13(A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13)is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura[J].Arterioscler Thromb Vasc Biol,2018,38(11):2731-2743.
[37] RAO L,BU L L,MA L,et al.Platelet-facilitated photothermal therapy of head and neck squamous cell carcinoma[J].Angew Chem Int Ed Engl,2018,57(4):986-991.
[38] TANAKA H,HORIOKA K,HASEBE T,et al.Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib:A novel therapy exploiting tumor-platelet interactions[J].Int J Cancer,2022,150(10):1640-1653.
[39] ZHANG X,WANG J,CHEN Z,et al.Engineering PD-1-presenting platelets for cancer immunotherapy[J].Nano Lett,2018,18(9):5716-5725.
[40] HU Q,SUN W,WANG J,et al.Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy[J].Nat Biomed Eng,2018,2(11):831-840.
[41] TANG S,ZHANG F,GONG H,et al.Enzyme-powered Janus platelet cell robots for active and targeted drug delivery[J].Sci Robot,2020,5(43):eaba6137.
[42] SHI J,KANTOFF P W,WOOSTER R,et al.Cancer nanomedicine:Progress,challenges and opportunities[J].Nat Rev Cancer,2017,17(1):20-37.
[43] CORREA S,BOEHNKE N,BARBERIO A E,et al.Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry[J].ACS Nano,2020,14(2):2224-2237.
[44] CHOI B,PARK W,PARK S B,et al.Recent trends in cell membrane-cloaked nanoparticles for therapeutic applications[J].Methods,2020(177):2-14.
[45] YAN H,SHAO D,LAO Y H,et al.Engineering cell membrane-based nanotherapeutics to target inflammation[J].Adv Sci(Weinh),2019,6(15):1900605.
[46] JURASZ P,ALONSO-ESCOLANO D,RADOMSKI M W.Platelet--cancer interactions:Mechanisms and pharmacology of tumour cell-induced platelet aggregation[J].Br J Pharmacol,2004,143(7):819-826.
[47] SONG Y,HUANG Z,LIU X,et al.Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient(ApoE-/-)mice[J].Nanomedicine,2019,15(1):13-24.
[48] GENG B,CHEN X,CHI J,et al.Platelet membrane-coated alterbrassicene A nanoparticle inhibits calcification of the aortic valve by suppressing phosphorylation P65 NF-κB[J].Theranostics,2023,13(11):3781-3793.
[49] HUANG R,CAI G-Q,LI J,et al.Platelet membrane-camouflaged silver metal-organic framework drug system against infections caused by methicillin-resistant Staphylococcus aureus[J].J Nanobiotechnology,2021,19(1):229.
[50] JIANG H,TANG C,WEN Y,et al.Enhanced antitumor efficacy of novel biomimetic platelet membrane-coated tetrandrine nanoparticles in nonsmall cell lung cancer[J].Mol Pharm,2023,20(11):5463-5475.
[51] REN D,WILLIAMS G R,ZHANG Y,et al.Mesoporous doxorubicin-loaded polydopamine nanoparticles coated with a platelet membrane suppress tumor growth in a murine model of human breast cancer[J].ACS Appl Bio Mater,2022,5(1):123-133.
[52] ZHOU M,LAI W,LI G,et al.Platelet membrane-coated and VAR2CSA malaria protein-functionalized nanoparticles for targeted treatment of primary and metastatic cancer[J].ACS Appl Mater Interfaces,2021,13(22):25635-25648.
[53] WU L,XIE W,ZAN H M,et al.Platelet membrane-coated nanoparticles for targeted drug delivery and local chemo-photothermal therapy of orthotopic hepatocellular carcinoma[J].J Mater Chem B,2020,8(21):4648-4659.
[54] PEI W,HUANG B,CHEN S,et al.Platelet-mimicking drug delivery nanoparticles for enhanced chemo-photothermal therapy of breast cancer[J].Int J Nanomedicine,2020(15):10151-10167.
[55] XU L,GAO F,FAN F,et al.Platelet membrane coating coupled with solar irradiation endows a photodynamic nanosystem with both improved antitumor efficacy and undetectable skin damage[J].Biomaterials,2018(159):59-67.
[56] WAN G,CHEN X,GOU R,et al.Platelet membrane-based biochemotactic-targeting nanoplatform combining PDT with EGFR inhibition therapy for the treatment of breast cancer[J].Biomater Sci,2024,12(3):691-709.
[57] MENG F,ZHAI X,MA J,et al.Enzyme-induced shape-shifting peptide nanocarrier coloaded with paclitaxel and dipyridamole inhibits platelet function and tumor metastasis[J].ACS Appl Mater Interfaces,2024,16(1):166-177.
[58] BAHMANI B,GONG H,LUK B T,et al.Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors[J].Nat Commun,2021,12(1):1999.
[59] ZUO H,TAO J,SHI H,et al.Platelet-mimicking nanoparticles co-loaded with W18O49 and metformin alleviate tumor hypoxia for enhanced photodynamic therapy and photothermal therapy[J].Acta Biomater,2018(80):296-307.
[60] CHEN L,ZHOU Z,HU C,et al.Platelet membrane-coated nanocarriers targeting plaques to deliver Anti-CD47 antibody for atherosclerotic therapy[J].Research(Wash D C),2022(2022):9845459.
[61] YIN M,LIN J,YANG M,et al.Platelet membrane-cloaked selenium/ginsenoside Rb1 nanosystem as biomimetic reactor for atherosclerosis therapy[J].Colloids Surf B Biointerfaces,2022(214):112464.
[62] WEI X,YING M,DEHAINI D,et al.Nanoparticle functionalization with platelet membrane enables multifactored biological targeting and detection of atherosclerosis[J].ACS Nano,2018,12(1):109-116.
[63] WANG B,CHEN G,URABE G,et al.A paradigm of endothelium-protective and stent-free anti-restenotic therapy using biomimetic nanoclusters[J].Biomaterials,2018(178):293-301.
[64] SU T,HUANG K,MA H,et al.Platelet-inspired nanocells for targeted heart repair after ischemia/reperfusion injury[J].Adv Funct Mater,2019,29(4):1803567.
[65] LI M,LI J,CHEN J,et al.Platelet membrane biomimetic magnetic nanocarriers for targeted delivery and in situ generation of nitric oxide in early ischemic stroke[J].ACS Nano,2020,14(2):2024-2035.
[66] DU S,GUAN Y,XIE A,et al.Extracellular vesicles:A rising star for therapeutics and drug delivery[J].J Nanobiotechnology,2023,21(1):231.
[67] FERREIRA P M,BOZBAS E,TANNETTA S D,et al.Mode of induction of platelet-derived extracellular vesicles is a critical determinant of their phenotype and function[J].Sci Rep,2020,10(1):18061.
[68] PEREZ-PUJOL S,MARKER P H,KEY N S.Platelet microparticles are heterogeneous and highly dependent on the activation mechanism:Studies using a new digital flow cytometer[J].Cytometry A,2007,71(1):38-45.
[69] MA Q,FAN Q,HAN X,et al.Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy[J].J Control Release,2021(329):445-453.
[70] JOHNSON J,LAW S Q K,SHOJAEE M,et al.First-in-human clinical trial of allogeneic,platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing[J].J Extracell Vesicles,2023,12(7):e12332.